tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CNTA Stock Latest News

Positive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class
RatingsPositive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class
4d ago
CNTA
Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile
PremiumRatings
Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile
4d ago
CNTA
Centessa Pharmaceuticals Positioned for Leadership in Orexin Agonist Market with Promising ORX750 Candidate
PremiumRatings
Centessa Pharmaceuticals Positioned for Leadership in Orexin Agonist Market with Promising ORX750 Candidate
12d ago
CNTA
Centessa Pharmaceuticals Approves Key Resolutions at AGM
PremiumCompany Announcements
Centessa Pharmaceuticals Approves Key Resolutions at AGM
29d ago
8K
CNTA
Centessa Pharmaceuticals Gains FDA Clearance for ORX142 Study
PremiumCompany Announcements
Centessa Pharmaceuticals Gains FDA Clearance for ORX142 Study
1M ago
8K
CNTA
Centessa announces clearance of IND for ORX142
PremiumThe FlyCentessa announces clearance of IND for ORX142
1M ago
CNTA
Centessa Pharmaceuticals: Buy Rating Affirmed on Promising Orexin Agonist Program and Innovative Trial Design
Premium
Ratings
Centessa Pharmaceuticals: Buy Rating Affirmed on Promising Orexin Agonist Program and Innovative Trial Design
1M ago
CNTA
Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating
Premium
Ratings
Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating
1M ago
CNTA
Centessa Pharmaceuticals Appoints New Chief Accounting Officer
PremiumCompany Announcements
Centessa Pharmaceuticals Appoints New Chief Accounting Officer
2M ago
8K
CNTA
Centessa initiated with a Buy at Needham
PremiumThe Fly
Centessa initiated with a Buy at Needham
2M ago
CNTA
Positive Outlook on Centessa Pharmaceuticals Driven by ORX750’s Promising Potential and Market Growth
PremiumRatings
Positive Outlook on Centessa Pharmaceuticals Driven by ORX750’s Promising Potential and Market Growth
2M ago
CNTA
Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
PremiumCompany Announcements
Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
2M ago
CNTA
Centessa reports Q1 EPS (20c) vs (38c) last year
PremiumThe FlyCentessa reports Q1 EPS (20c) vs (38c) last year
2M ago
CNTA
Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
Premium
The Fly
Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
2M ago
Z
SN
Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
Premium
The Fly
Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
2M ago
ADM
AWR
Centessa initiated with a Buy at Chardan
PremiumThe Fly
Centessa initiated with a Buy at Chardan
2M ago
CNTA
Centessa Pharmaceuticals’ ORX750: Promising Developments and Buy Rating by David Risinger
PremiumRatings
Centessa Pharmaceuticals’ ORX750: Promising Developments and Buy Rating by David Risinger
3M ago
CNTA
Centessa initiated with an Overweight at Piper Sandler
PremiumThe Fly
Centessa initiated with an Overweight at Piper Sandler
4M ago
CNTA
Centessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline
PremiumRatings
Centessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline
4M ago
CNTA
Centessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating
PremiumRatingsCentessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating
4M ago
CNTA
Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating
Premium
Ratings
Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating
4M ago
CNTA
Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
Premium
Company Announcements
Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
4M ago
CNTA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >